Preeclampsia: New insights

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 3, 2007, Pages 213-220

  Shah, Dinesh M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MERITER HOSPITAL   (United States)

Author keywords

Angiotensin II; Preeclampsia; Renin angiotensin system; Soluble endoglin; Soluble fms like tyrosine kinase; Vascular endothelial growth factor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; AUTOANTIBODY; ENDOGLIN; RENIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

CYTOTROPHOBLAST; GLOMERULOPATHY; HUMAN; HYPERTENSION; KIDNEY INJURY; PATHOGENESIS; PLACENTA; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TROPHOBLAST;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; ANTIGENS, CD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; PLACENTA; PLACENTAL CIRCULATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; RENIN-ANGIOTENSIN SYSTEM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 34247199366     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3280d942e9     Document Type: Review

References (118)

1. Page EW. On the pathogenesis of preeclampsia and eclampsia. J Obstet Gynaecol Br Commonw 1972; 79:883-894.
2. Combs CA, Katz MA, Kitzmiller JL, Brescia RJ. Experimental preeclampsia produced by chronic constriction of the lower aorta: validation with longitudinal blood pressure measurements in conscious rhesus monkeys. Am J Obstet Gynecol 1993; 169:215-223.
3. Gervasi MT, Chaiworapongsa T, Pacora P, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001; 185:792-797.
4. Many A, Hubel CA, Fisher SJ, et al. Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am J Pathol 2000; 156:321-331.
5. Nielsen AH, Schauser KH, Poulsen K. Current topic: the uteroplacental renin-angiotensin system. Placenta 2000; 21:468-477.
6. Ramsey E, Harris J. Comparison of uteroplacental vasculature and circulation in the rhesus monkey and man. Contributions to Embryology, No. 261. Washington, USA: Carnegie Institution of Washington 1966; 38:59-70.
7. Ramsey EM, Corner GW, Donner MW, Stran HM. Radioangiographic studies of circulation in the maternal placenta of the rhesus monkey: preliminary report. Proc Natl Acad Sci U S A 1960; 46:1003-1008.
8. Brosens I, Dixon HG. The anatomy of the maternal side of the placenta. J Obstet Gynaecol Br Commonw 1966; 73:357-363.
9. Ramsey EM. Circulation in the intervillous space of the primate placenta. Am J Obstet Gynecol 1962; 84:1649-1663.
10. Pijnenborg R, Dixon G, Robertson WB, Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta 1980; 1:3-19.
11. Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98:648-655.
12. De Wolf F, Brosens I, Robertson WB. Ultrastructure of uteroplacental arteries. Contrib Gynecol Obstet 1982; 9:86-99.
13. Meekins JW, Pijnenborg R, Hanssens M, et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe preeclamptic pregnancies. Br J Obstet Gynaecol 1994; 101:669-674.
14. Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol 2002; 187:1416-1423.
15. Damsky CH, Fisher SJ. Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. Curr Opin Cell Biol 1998; 10:660-666.
16. Lala PK, Chakraborty C. Factors regulating trophoblast migration and invasiveness: possible derangements contributing to preeclampsia and fetal injury. Placenta 2003; 24:575-587.
17. Red-Horse K, Zhou Y, Genbacev O, et al. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest 2004; 114:744-754.
18. Albrecht ED, Bonagura TW, Burleigh DW, et al. Suppression of extravillous trophoblast invasion of uterine spiral arteries by estrogen during early baboon pregnancy. Placenta 2006; 27:483-490.
19. Anteby EY, Greenfield C, Natanson-Yaron S, et al. Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9. Mol Hum Reprod 2004; 10:229-235.
20. Bamberger AM, Minas V, Kalantaridou SN, et al. Corticotropin-releasing hormone modulates human trophoblast invasion through carcinoembryonic antigen-related cell adhesion molecule-1 regulation. Am J Pathol 2006; 168: 141-150.
21. Bass KE, Morrish D, Roth I, et al. Human cytotrophoblast invasion is upregulated by epidermal growth factor: evidence that paracrine factors modify this process. Dev Biol 1994; 164:550-561.
22. Bauer S, Pollheimer J, Hartmann J, et al. Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures. J Clin Endocrinol Metab 2004; 89:812-822.
23. Caniggia I, Winter JL. Adriana and Luisa Castellucci Award Lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and preeclamptic pregnancies - a review. Placenta 2002; 23 (Suppl A): S47-S57.
24. Canning MT, Postovit LM, Clarke SH, Graham CH. Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res 2001; 267:88-94.
25. Crocker IP, Wareing M, Ferris GR, et al. The effect of vascular origin, oxygen, and tumour necrosis factor alpha on trophoblast invasion of maternal arteries in vitro. J Pathol 2005; 206:476-485.
26. Crossey PA, Pillai CC, Miell JP. Altered placental development and intrauterine growth restriction in IGF binding protein-1 transgenic mice. J Clin Invest 2002; 110:411-418.
27. Genbacev O, McMaster MT, Fisher SJ. A repertoire of cell cycle regulators whose expression is coordinated with human cytotrophoblast differentiation. Am J Pathol 2000; 157:1337-1351.
28. Gleeson LM, Chakraborty C, McKinnon T, Lala PK. Insulin-like growth factorbinding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein kinase pathway. J Clin Endocrinol Metab 2001; 86:2484-2493.
29. Graham CH, Postovit LM, Park H, et al. Adriana and Luisa Castellucci Award Lecture 1999. Role of oxygen in the regulation of trophoblast gene expression and invasion. Placenta 2000; 21:443-450.
30. Hanna J, Goldman-Wohl D, Hamani Y, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006; 12:1065-1074.
31. Hayashi M, Sakata M, Takeda T, et al. Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension. Endocrinology 2005; 146:4682-4689.
32. Irving JA, Lala PK. Functional role of cell surface integrins on human trophoblast cell migration: regulation by TGF-beta, IGF-II, and IGFBP-1. Exp Cell Res 1995; 217:419-427.
33. Karmakar S, Das C. Regulation of trophoblast invasion by IL-1beta and TGF-beta. Am J Reprod Immunol 2002; 48:210-219.
34. Karmakar S, Dhar R, Das C. Inhibition of cytotrophoblastic (JEG-3) cell invasion by interleukin 12 involves an interferon gamma-mediated pathway. J Biol Chem 2004; 279:55297-55307.
35. Lacroix MC, Guibourdenche J, Fournier T, et al. Stimulation of human trophoblast invasion by placental growth hormone. Endocrinology 2005; 146:2434-2444.
36. Librach CL, Feigenbaum SL, Bass KE, et al. Interleukin-1 beta regulates human cytotrophoblast metalloproteinase activity and invasion in vitro. J Biol Chem 1994; 269:17125-17131.
37. Liu J, Chakraborty C, Graham CH, et al. Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase. Exp Cell Res 2003; 286:138-151.
38. O'Brien PJ, Koi H, Parry S, et al. Thrombin receptors and proteaseactivated receptor-2 in human placentation: receptor activation mediates extravillous trophoblast invasion in vitro. Am J Pathol 2003; 163:1245-1254.
39. Pollheimer J, Loregger T, Sonderegger S, et al. Activation of the canonical wingless/T-cell factor signaling pathway promotes invasive differentiation of human trophoblast. Am J Pathol 2006; 168:1134-1147.
40. Renaud SJ, Macdonald-Goodfellow SK, Graham CH. Coordinated regulation of trophoblast invasiveness by macrophages and interleukin 10. Biol Reprod, 6 December 2006. [E-pub ahead of print]
41. Renaud SJ, Postovit LM, Macdonald-Goodfellow SK, et al. Activated macrophages inhibit human cytotrophoblast invasiveness in vitro. Biol Reprod 2005; 73:237-243.
42. Soghomonians A, Barakat AI, Thirkill TL, Douglas GC. Trophoblast migration under flow is regulated by endothelial cells. Biol Reprod 2005; 73:14-19.
43. Wright JK, Dunk CE, Perkins JE, et al. EGF modulates trophoblast migration through regulation of Connexin 40. Placenta 2006; 27 (Suppl A):S114-S121.
44. Xia Y, Wen HY, Kellems RE. Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation. J Biol Chem 2002; 277: 24601-24608.
45. Zhou Y, Chiu K, Brescia RJ, et al. Increased depth of trophoblast invasion after chronic constriction of the lower aorta in rhesus monkeys. Am J Obstet Gynecol 1993; 169:224-229.
46. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype: one cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99:2152-2164.
47. Zhou Y, Fisher SJ, Janatpour M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate: a strategy for successful endovascular invasion? J Clin Invest 1997; 99:2139-2151.
48. Ihara Y, Taii S, Mori T. Expression of renin and angiotensinogen genes in the human placental tissues. Endocrinol Jpn 1987; 34:887-896.
49. Li C, Yu Z, Shah D. Authenticity and cellular localization of prorenin in human placenta [abstract]. J Soc Gynecol Invest 2001; 8 (Suppl 1):207A.
50. Li X, Shams M, Zhu J, et al. Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction: angiotensin II stimulates the release of vasorelaxants. J Clin Invest 1998; 101:442-454.
51. Shaw KJ, Do YS, Kjos S, et al. Human decidua is a major source of renin. J Clin Invest 1989; 83:2085-2092.
52. Morgan T, Craven C, Ward K. Human spiral artery renin-angiotensin system. Hypertension 1998; 32:683-687.
53. Li C, Ansari R, Yu Z, Shah D. Definitive molecular evidence of renin-angiotensin system in human uterine decidual cells. Hypertension 2000; 36:159-164.
54. Shah DM, Higuchi K, Inagami T, Osteen KG. Effect of progesterone on renin secretion in endometrial stromal, chorionic trophoblast, and mesenchymal monolayer cultures. Am J Obstet Gynecol 1991; 164:1145-1150.
55. Yan JS, Guo LH, Liu J, Wang H. Modulation of the secretion of active renin in human decidual cells by progesteron [in Chinese]. Sheng Li Xue Bao 1999; 51:211-218.
56. Yu Z, Li C, Shah D. Prorenin expression in the course of in vitro decidualization of human endometrial stromal cells: effects of progesterone versus cyclic AMP. J Soc Gynecol Invest 2001; 9 (Suppl 1):220A.
57. Skinner SL, Lumbers ER, Symonds EM. Analysis of changes in the rennin-angiotensin system during pregnancy. Clin Sci 1972; 42:479-488.
58. Brown MA, Zammit VC, Mitar DA, Whitworth JA. Renin-aldosterone relationships in pregnancy-induced hypertension. Am J Hypertens 1992; 5:366-371.
59. Symonds EM, Broughton Pipkin F, Craven DJ. Changes in the renin-angiotensin system in primigravidae with hypertensive disease of pregnancy. Br J Obstet Gynaecol 1975; 82:643-650.
60. Abdul-Karim R, Assali N. Pressor response to angiotonin in pregnant and nonpregnant women. Am J Obstet Gynecol 1961; 82:246-251.
61. Gant NF, Daley GL, Chand S, et al. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52:2682-2689.
62. Shah DM, Banu JM, Chirgwin JM, Tekmal RR. Reproductive tissue renin gene expression in preeclampsia. Hypertens Pregnancy 2000; 19:341-351.
63. Merrill DC, Karoly M, Chen K, et al. Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 2002; 18:239-245.
64. Hayashi RH, Becker RA, Evans GT, et al. Prospective study of angiotensin II response to positional change in pregnancy-induced hypertension. Am J Obstet Gynecol 1977; 128:872-878.
65. Brown MA, Wang J, Whitworth JA. The renin-angiotensin-aldosterone system in preeclampsia. Clin Exp Hypertens 1997; 19:713-726.
66. Takimoto E, Ishida J, Sugiyama F, et al. Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen. Science 1996; 274:995-998.
67. Saito T, Ishida J, Takimoto-Ohnishi E, et al. An essential role for angiotensin II type 1a receptor in pregnancy-associated hypertension with intrauterine growth retardation. Faseb J 2004; 18:388-390.
68. Samani NJ, Godfrey NP, Major JS, et al. Kidney renin mRNA levels in the early and chronic phases of two-kidney, one clip hypertension in the rat. J Hypertens 1989; 7:105-112.
69. Abitbol MM, Pirani CL, Ober WB, et al. Production of experimental toxemia in the pregnant dog. Obstet Gynecol 1976; 48:537-548.
70. Alexander BT, Kassab SE, Miller MT, et al. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 2001; 37:1191-1195.
71. Cavanagh D, Rao PS, Tsai CC, O'Connor TC. Experimental toxemia in the pregnant primate. Am J Obstet Gynecol 1977; 128:75-85.
72. Hill PA, Fairley KF, Kincaid-Smith P, et al. Morphologic changes in the renal glomerulus and the juxtaglomerular apparatus in human preeclampsia. J Pathol 1988; 156:291-303.
73. Dzau VJ, Gonzalez D, Ellison K, et al. Characterization of purified rabbit uterine renin: influence of pregnancy on uterine inactive renin. Endocrinology 1987; 120:358-364.
74. Zamudio S, Leslie KK, White M, et al. Low serum estradiol and high serum progesterone concentrations characterize hypertensive pregnancies at high altitude. J Soc Gynecol Invest 1994; 1:197-205.
75. Chesley LC, Talledo E, Bohler CS, Zuspan FP. Vascular reactivity to angiotensin II and norepinephrine in pregnant women. Am J Obstet Gynecol 1965; 91:837-842.
76. Pueyo ME, Arnal JF, Rami J, Michel JB. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am J Physiol 1998; 274:C214-C220.
77. Schobel HP, Fischer T, Heuszer K, et al. Preeclampsia: a state of sympathetic overactivity. N Engl J Med 1996; 335:1480-1485.
78. Fitzgerald DJ, Rocki W, Murray R, et al. Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet 1990; 335:751-754.
79. Lopatin DA, Ailamazian EK, Dmitrieva RI, et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999; 17:1179-1187.
80. Maxwell CV, Tao QF, Seely EW, et al. Regulation of the sodium pump in pregnancy-related tissues in preeclampsia. Am J Obstet Gynecol 1998; 179:28-34.
81. AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7:1003-1009.
82. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000; 407:94-98.
83. AbdAlla S, Abdel-Baset A, Lother H, et al. Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension. J Mol Neurosci 2005; 26:185-192.
84. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001; 276:39721-39726.
85. Bird IM, Zheng J, Cale JM, Magness RR. Pregnancy induces an increase in angiotensin II type-1 receptor expression in uterine but not systemic artery endothelium. Endocrinology 1997; 138:490-498.
86. McMullen JR, Gibson KJ, Lumbers ER, Burrell JH. Selective down-regulation of AT2 receptors in uterine arteries from pregnant ewes given 24-h intravenous infusions of angiotensin II. Regul Pept 2001; 99:119-129.
87. McMullen JR, Gibson KJ, Lumbers ER, et al. Interactions between AT1 and AT2 receptors in uterine arteries from pregnant ewes. Eur J Pharmacol 1999; 378:195-202.
88. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103:945-952.
89. Dechend R, Gratze P, Wallukat G, et al. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 2005; 45:742-746.
90. Bobst SM, Day MC, Gilstrap LC 3rd, et al. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens 2005; 18:330-336.
91. Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000; 101:2382-2387.
92. Dechend R, Viedt C, Muller DN, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003; 107: 1632-1639.
93. Thway TM, Shlykov SG, Day MC, et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 2004; 110:1612-1619.
94. Walther T, Wallukat G, Jank A, et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 2005; 46:1275-1279.
95. Yamamoto T, Yoshimura S, Geshi Y, et al. Anti ssDNA and dsDNA antibodies in preeclampsia. Asia Oceania J Obstet Gynaecol 1994; 20:93-99.
96. Sharkey AM, Charnock-Jones DS, Boocock CA, et al. Expression of mRNA for vascular endothelial growth factor in human placenta. J Reprod Fertil 1993; 99:609-615.
97. Cooper JC, Sharkey AM, Charnock-Jones DS, et al. VEGF mRNA levels in placentae from pregnancies complicated by preeclampsia. Br J Obstet Gynaecol 1996; 103:1191-1196.
98. Clark DE, Smith SK, He Y, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59:1540-1548.
99. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
100. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88:5555-5563.
101. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
102. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190:1541-1547; discussion 1547-1550.
103. Park CW, Park JS, Shim SS, et al. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of midtrimester genetic amniocentesis is a risk factor for preeclampsia. Am JObstet Gynecol 2005; 193:984-989.
104. Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) and soluble Flt-1 by oxygen: a review. Placenta 2000; 21 (Suppl A):S16-S24.
105. Barleon B, Siemeister G, Martiny-Baron G, et al. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 1997; 57:5421-5425.
106. Lash GE, Taylor CM, Trew AJ, et al. Vascular endothelial growth factor and placental growth factor release in cultured trophoblast cells under different oxygen tensions. Growth Factors 2002; 20:189-196.
107. Li H, Gu B, Zhang Y, et al. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005; 26:210-217.
108. Rajakumar A, Brandon HM, Daftary A, et al. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004; 25:763-769.
109. Rajakumar A, Michael HM, Rajakumar PA, et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005; 26:563-573.
110. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005. This paper presents clinical evidence of the elevation of soluble endoglin before the clinical manifestation of preeclampsia.
111. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642-649. This paper presents experimental evidence that soluble endoglin may contribute to the renal manifestations of preeclampsia.
112. Murakami Y, Kobayashi T, Omatsu K, et al. Exogenous vascular endothelial growth factor can induce preeclampsia-like symptoms in pregnant mice. Semin Thromb Hemost 2005; 31:307-313.
113. Krysiak O, Bretschneider A, Zhong E, et al. Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. Circ Res 2005; 97:1253-1261.
114. Matsubara K, Nagamatsu T, Fujii T, et al. Lymphokine-activated killer cells induced from decidual lymphocytes reduce the angiogenic activity of trophoblasts by enhancing the release of soluble fms-like tyrosine kinase-1 from trophoblasts: an implication for the pathophysiology of preeclampsia. J Reprod Immunol 2005; 68:27-37.
115. Germain AM, Romanik MC, Guerra I, et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension 2007; 49:90-95.
116. Khan F, Belch JJ, MacLeod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 2005; 46:1123-1128.
117. Shah DM. Role of the renin-angiotensin system in the pathogenesis of preeclampsia. Am J Physiol Renal Physiol 2005; 288:F614-F625.
118. Ayuk PT, Matijevic R. Placental ischaemia is a consequence rather than a cause of preeclampsia. Med Hypotheses 2006; 67:792-795.